EUCTR2014-003514-91-Outside-EU/EEA进行中（未招募）不适用
A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with that of a Licensed Meningococcal ACWY Polysaccharide Vaccine (Menomune®) Administered to Healthy Children 2 to 10 Years of Age
ovartis Vaccines and Diagnostics S.r.l.0 个研究点目标入组 1,500 人开始时间: 2014年9月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 2-10 years of age inclusive whose parents or legal guardians have given written informed consent at the time of enrollment;
- •2. available for all visits and telephone calls (parents or legal guardians) scheduled for the study;
- •3. in good health as determined by:
- •medical history,
- •physical assessment,
- •clinical judgment of the investigator;
- •4. up to date with primary course and booster vaccines [BCG, and 4 doses of diphtheria-tetanus-pertussis vaccine (DTP), oral polio vaccine (OPV) or inactivated polio vaccine (IPV), H. influenzae type b vaccine (Hib), measles-mumps-rubella vaccine (MMR) and hepatitis A or B,
- •according to the Argentinean vaccine calendar and subject age].
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1500
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. whose parent or legal guardian is unwilling or unable to give written informed consent to participate in the study;
- •2. whose parent or legal guardian is perceived to be unreliable or unavailable for the duration of the study period;
- •3. who had a previous or suspected disease caused by N. meningitidis;
- •4. who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrollment;
- •5. who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational);
- •6. who have received any investigational agents or vaccines within 90 days prior to enrollment or who expect to receive an investigational agent or vaccine prior to the completion of the study;
- •7. who have received any licensed vaccines within one month prior to enrollment or for whom receipt of a licensed vaccine is anticipated within one month after vaccination (Exception: Influenza vaccine may be administered up to 15 days prior to study vaccination and no less
- •than 15 days after study vaccination);
- •8. who have received a live viral vaccine within 60 days prior to enrollment;
- •9. who have experienced, within the 7 days prior to enrollment, significant acute or chronic infection (for example requiring systemic antibiotic treatment or antiviral therapy) or have experienced fever (defined as axillary temperature =38°C) within 3 days prior to
- •enrollment;
- •10. who have any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS), or blood dyscrasias, with signs
- •of cardiac or renal failure or severe malnutrition). (Exception: Subjects with mild asthma are eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic
- •corticosteroids are not eligible for enrollment);
- •11. who have epilepsy or any progressive neurological disease;
- •12. who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine component;
- •13. who have a known or suspected impairment/alteration of immune
- •function, either congenital or acquired or resulting from (for example):
- •receipt of immunosuppressive therapy within 30 days prior to enrollment (any systemic corticosteroid administered for more than 5 days, or in a daily dose >1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy),
- •receipt of immunostimulants,
- •receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study,
- •Common childhood exanthematous diseases (varicella, mumps, measles, rubella) occurring 6 weeks prior to vaccination;
- •14. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;
- •15. who have Down's syndrome or other known cytogenic disorders;
- •16. whose families are planning to leave the area of the study site before the end of the study period;
- •17. who have any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
研究者
相似试验
进行中（未招募）
不适用
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adultsovartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.MedDRA version: 17.1Level: PTClassification code 10027280Term: Meningococcal sepsisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: PTClassification code 10027249Term: Meningitis meningococcalSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: LLTClassification code 10027276Term: Meningococcal meningitisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: LLTClassification code 10040081Term: Septicaemia meningococcalSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: LLTClassification code 10040048Term: Sepsis meningococcalSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-003504-79-Outside-EU/EEAovartis Vaccines & Diagnostics, Inc.3,539
进行中（未招募）
1 期
Clinical study in adults 50-64 years old to evaluate immunogenicity and safety of adjuvanted flu vaccine in comparison with a licensed non-adjuvanted flu vaccineProphylaxis of InfluenzaMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-001721-40-DESeqirus UK Limited2,018
进行中（未招募）
1 期
Clinical study in adults 50-64 years old to evaluate immunogenicity and safety of adjuvanted flu vaccine in comparison with a licensed non-adjuvanted flu vaccineEUCTR2021-001721-40-EESeqirus UK Limited2,018
进行中（未招募）
1 期
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older.CTIS2023-503763-42-00Seqirus UK Limited6,300
进行中（未招募）
1 期
A Phase 3, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy Toddlers 12 Months of Age, Compared to Single Dose of Meningococcal C Conjugate VaccineTo demonstrate non-inferiority of MenACWY vaccine to that of MenC vaccinegiven to healthy toddlers, as measured by the percentage of subjects with serumbactericidal assay using human complement (hSBA) titers =8 against N.meningitidis serogroup C, at 28 days after the vaccination.MedDRA version: 16.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000145-39-CZovartis Vaccines and Diagnostics s.r.l1,000